ION-ZC1 – Acute Intravenous Toxicity in Mice

Verified Intravenous Toxicity Study Confirms ION-ZC1 Is Safe at 667 mg/kg in Mice

Establishing systemic safety is essential in the preclinical development of any bioactive compound. In the ION-ZC1, the core ionic complex found in Ion Gel ZCM-25®, rigorous scientific evaluation has proven its biocompatibility and non-toxicity at significantly high doses.

A GLP-compliant intravenous toxicity study, conducted in 2015 by INDEVION Biotechnology Research Ltd. for the University of Debrecen, confirms that ION-ZC1 is non-toxic at a dose of 667 mg/kg, a level substantially higher than what would be used in clinical practice. These findings support the safe systemic profile of ION-ZC1 and reinforce its potential in advanced delivery systems beyond topical applications.

Study Overview: Acute IV Toxicity of ION-ZC1

The purpose of the intravenous toxicity study was to evaluate acute systemic toxicity following a single high-dose intravenous (IV) administration of ION-ZC1 in a healthy animal model. The study complied with international Good Laboratory Practices (GLP), ensuring the integrity and reliability of data.

Toxicity Study Design:

• Test model: Healthy mice (n = 30)
• Dose: 667 mg/kg via intravenous injection
• Observation period: 14 consecutive days
• Endpoints evaluated:
  • Clinical signs
  • Body weight monitoring
  • Behavioral observation
  • Complete necropsy and organ pathology

Key Results:

• No abnormal clinical signs observed
• No changes in body weight
• No behavioral deviations
• No pathological findings at necropsy

These results confirmed that ION-ZC1 exhibits no acute systemic toxicity, even when delivered intravenously at a dose that exceeds standard pharmacological concentrations by several folds. The intravenous toxicity study thus serves as critical preclinical evidence of ION-ZC1’s exceptional tolerability.

What Is ION-ZC1?

ION-ZC1 is the active pharmacological complex used in Ion Gel ZCM-25®, a Class II Medical Device approved by COFEPRIS in Mexico for wound healing and infection prevention. It is built on a proprietary platform known as IBAL (Ion Biotechnology Aqueous Ligands).

This platform is composed of coordinated cationic minerals, including:

• Zinc (Zn²⁺) – essential for tissue repair and immune modulation
• Copper (Cu²⁺) – known for its broad-spectrum antimicrobial properties
• Magnesium (Mg²⁺) – anti-inflammatory and stabilizer of cellular functions
• Sulfur and Hydrogen ions contribute to redox homeostasis and cellular metabolism

These ions exhibit antibacterial, antiviral, antifungal, antioxidant, and anti-inflammatory properties while maintaining an exceptionally low toxicity profile​.

Pharmacological Significance of the IV Study

While ION-ZC1 is predominantly used topically in Ion Gel ZCM-25®, the intravenous toxicity study offers critical data on its systemic behavior, which includes:

• Maximum Tolerated Dose (MTD) beyond 667 mg/kg
• No organ accumulation, confirmed by pharmacokinetic studies
• Controlled redox behavior at physiological pH
• Clearance within 8–12 hours post-application​

This reinforces ION-ZC1’s potential for extended medical applications, including:

• Transdermal systems for chronic inflammation
• Injectable formulations for immune modulation
• Redox-activated systemic therapies for oncology

The data from this intravenous toxicity study can also help support future clinical trial applications, especially where systemic administration routes are considered.

Clinical Safety Aligned with Systemic Tolerability

Although the study addresses IV administration, its results directly support the clinical safety profile of topical Ion Gel ZCM-25®.

Clinical cases using Ion Gel ZCM-25®—especially for diabetic foot ulcers, post-surgical wounds, and chronic skin infections—show:

• Fast recovery without adverse events
• No systemic toxicity, even with high-frequency application
• Improved outcomes in patients with comorbidities (e.g., diabetes, hypertension, peripheral vascular disease)​

In one case, a 56-year-old diabetic patient treated with Ion Gel ZCM-25® and silver dressing over 104 days showed complete wound healing, avoided skin graft surgery, and experienced no signs of infection or systemic reaction​.

This practical evidence reinforces the outcomes of the intravenous toxicity study by showing consistent safety results in both systemic and localized applications.

Additional Preclinical Findings Support Safety

The intravenous toxicity study is part of a broader body of preclinical evaluations:

• Pharmacokinetic studies conducted by Universidad de San Luis Potosí confirmed that metallic ions from ION-ZC1 appear in the bloodstream within 1 hour of topical application and are cleared in 8–12 hours without accumulation​.
• Oxidative stress studies showed a 50% reduction in key ROS markers within 24 hours of topical application​.
• Microbial challenge tests proved that ION-ZC1 destroyed 36 pathogens, including multidrug-resistant strains such as MRSA and Acinetobacter baumannii​.

The robustness of the intravenous toxicity study adds validity to these findings and confirms ION-ZC1’s potential as a safe and multifunctional therapeutic platform.

Regulatory & Economic Impact

Regulatory Approval

• COFEPRIS Approval: Ion Gel ZCM-25® is classified as a Medical Device Class II, allowing broad clinical use in hospitals, clinics, and homes​.
• GMP Manufacturing: Produced under strict cGMP standards by Laboratorios Zeyco S.A. de C.V., ensuring high-quality consistency.

Health System Integration

The IMSS proposal submitted in 2024 estimates that nationwide adoption of Ion Gel ZCM-25® would generate:

• MXN $83.8 billion in annual cost savings
  • Due to faster healing, fewer infections, reduced hospital stays, and lower medication use​

These projections are made possible in part because the intravenous toxicity study verifies the safety margin required for long-term, high-frequency use, which is critical in chronic care settings.

A Future-Ready Bioactive Platform

ION-ZC1’s systemic safety, confirmed through the intravenous toxicity study, expands the scope of medical innovation using this compound. Potential development directions include:

• Redox-activated injectable immunotherapies
• Advanced regenerative medicine platforms
• Systemic treatments for inflammation and oxidative stress
• Smart wound care systems integrated with biosensors

Future formulations may reference this intravenous toxicity study as part of their regulatory filings for injectable or transdermal delivery models, given the established tolerability profile.

Conclusion: Science-Backed Safety, System-Wide Potential

The intravenous toxicity study at 667 mg/kg in mice has confirmed that ION-ZC1 is exceptionally well-tolerated, without any acute or subacute adverse effects. These results are critical for validating the compound’s use in both topical and systemic platforms.

Whether in chronic wound care, oncology, or infectious disease management, ION-ZC1 demonstrates unmatched potential to meet complex therapeutic demands safely. The repeated documentation of safety—especially the intravenous toxicity study—gives medical professionals and regulatory bodies the assurance needed for broader clinical adoption.

Learn More

Access supporting documentation: https://zcm25.com/resources